Abstract:Even though mAbs have attracted the biggest interest in the development of therapeutic proteins, next generation of therapeutics such as single-domain antibodies (sdAb) are propelling an increasing attention as new alternatives with appealing applications in different clinical areas. These constructs are small therapeutic proteins formed by a variable domain of the heavy chain of an antibody with multiple therapeutic and production benefits compared to their mAb counterparts. These proteins can be subjected to different bioconjugation processes to form single-domain antibody-drug conjugates (sdADC) and hence increase their therapeutic potency, and, akin to other therapeutic proteins, nanobodies and related products require dedicated analytical strategies to fully characterize their primary structure prior to their release to the market. In this study we report for the first time on the complete sequence characterization of a conjugated anti-EGFR 15 kDa sdADC by using cutting-edge top-down mass spectrometry strategies in combination with liquid chromatography (LC-TD-MS). Mass analysis revealed a highly homogeneous sample with one conjugated molecule. Subsequently, the reduced sdADC was submitted to different fragmentation techniques namely higher-energy collisional dissociation (HCD), electron-transfer dissociation (ETD), and ultraviolet photo-dissociation (UVPD) allowing to unambiguously asses the conjugation site with 16 diagnostic fragment ions and more than 85% of global sequence coverage. The sequence coverage of the non-reduced protein was significantly lower (around 33%), however the thorough analysis of the fragmentation spectra and the inclusion of the internal fragments corroborated the presence of the intra-molecular disulfide bridge along with the localization of the conjugation site. Altogether, our results pinpoint the complementary of the different fragmentation techniques to provide a thorough analytical characterization of sdAbs-formats even in the chromatographic time-scale, which allows a high-throughput and streamlined analysis of this kind of therapeutic proteins facilitating the implementation on dedicated R&D laboratories.

Rapid and Simultaneous Characterization of Drug Conjugation in Heavy and Light Chains of a Monoclonal Antibody Revealed by High-Resolution Ion Mobility Separations in SLIM

Automated Online Deconjugation of Antibody-Drug Conjugate for Small Molecule Drug Profiling

Enhanced Pharmacokinetic Bioanalysis of Antibody–drug Conjugates using Hybrid Immunoaffinity Capture and Microflow LC-MS/MS

Digestion-Free Middle-down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from ADCs

Development of fine-tuned top-down mass spectrometry strategies in the chromatographic time scale (LC-TD-MS) for the complete characterization of an anti EGFR single domain antibody-drug conjugate (sdADC)

Conjugation Site Analysis of Antibody-Drug-conjugates (adcs) by Signature Ion Fingerprinting and Normalized Area Quantitation Approach Using Nano-Liquid Chromatography Coupled to High Resolution Mass Spectrometry.

Digestion-Free Absolute Quantification of Conjugated Payload from ADCs Using Middle-Down Fragmentation Mass Spectrometry

Detection of antibody-conjugate payload in cynomolgus monkey serum by a high throughput capture LC-MS/MS bioanalysis method

In situ quantitative bioanalysis of monomethyl auristatin E-conjugated antibody-drug conjugates by flow cytometry.

Drug Deconjugation-assisted Peptide Mapping by LC-MS/MS to Identify Conjugation Sites and Quantify Site Occupancy for Antibody-drug Conjugates

In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry

A combination of multiple LC-MS approaches for the comprehensive characterization of cysteine-linked ADCs

Understanding the effects of site-specific light chain conjugation on antibody structure using hydrogen exchange-mass spectrometry (HX-MS)

A homogeneous high-DAR antibody-drug conjugate platform combining THIOMABTM antibodies and XTEN polypeptides

A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species

Rapid antibody conformational screening by matrix-assisted laser desorption/ionization hydrogen-deuterium exchange mass spectrometry

High-Throughput Automated Data Analysis workflow for ADC Biotransformation Characterization

A modelling approach to compare ADC deconjugation and systemic elimination rates of individual drug-load species using native ADC LC-MS data from human plasma

Development of a Single-Step Antibody–Drug Conjugate Purification Process with Membrane Chromatography

A simple and highly sensitive LC–MS workflow for characterization and quantification of ADC cleavable payloads

“Build your own” ADC mimics: Identification of non-toxic linker/payload mimics for HIC-based DAR determination, high-throughput optimization, and continuous flow conjugation